DURECT announces patient dosing in phase 2a trial of DUR-928 in alcoholic hepatitis
DURECT announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis. DUR-928, the lead investigational product in their Epigenetic Regulator Program, is an endogenous, first-in-class small molecule. April 25, 2018